Moderna (NASDAQ: MRNA) closed August 19, 2026 at $174.38, up roughly 177% from the previous session’s $62.96. It was the largest single-day gain in the company’s history, added close to $45 billion in market value, and pushed 185.1 million shares through the tape against a three-month average near 9.6 million. Merck rose 12.6% the same day to its highest level since 2009.
Then the reversal: about 20% lower the following session, briefly down 25% intraday, roughly $18 billion erased, with the 14-day RSI at 92.21, the most overbought reading in the stock’s history, before a partial rebound to around $145.
None of that volatility tells you anything about cancer care. What triggered it does.
The Catalyst
Merck and Moderna announced that intismeran autogene (V940/mRNA-4157) plus pembrolizumab met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in the Phase 3 INTerpath-001 trial. The study randomised 1,137 patients with completely resected stage IIB–IV cutaneous melanoma 2:1 to the combination or to pembrolizumab alone, and reportedly stopped at its first interim analysis with no new safety signals.
Read more details and insight’s into the trial on OncoDaily.
Three firsts sit in that sentence: the first positive Phase 3 for an individualized neoantigen therapy, the first for any mRNA-based cancer therapy, and the first regimen to add benefit on top of Keytruda monotherapy in adjuvant melanoma. Cancer vaccines had never succeeded in late-stage testing before.
Why the Reaction Was So Violent
The size of the move was a function of positioning, not just science. Most of the market had priced this trial to fail, BMO noted that investors had treated neoantigen studies as high-risk given mixed prior data and the novelty of the concept. Moderna had spent much of 2025 below $30 on collapsing COVID revenue, a failed CMV program, deep cost cuts, and a policy environment turning against mRNA. It had become one of biotech’s most heavily shorted large caps. Short sellers absorbed a reported $5.5 billion loss in a single day.
In other words, the stock did not reprice from neutral to positive. It repriced from “this probably fails” to “this is a platform,” in one session, on a press release.
The Data Nobody Has Seen
That press release contained no hazard ratio, no confidence interval, no p-value, no absolute RFS or DMFS separation, no median follow-up, and no adverse-event table. Full results are promised at an upcoming international medical meeting.
For clinicians, the magnitude is the whole question. The Phase 2b KEYNOTE-942 five-year update reported at ASCO 2026 produced a hazard ratio of 0.51, roughly halving recurrence or death. Moderna has described a 20% risk reduction as the program’s clinical benchmark. Those are different drugs in practice: 20% is real but modest set against a bespoke manufacturing burden, while 35–40% would genuinely reshape adjuvant melanoma discussions.
The Read-Across Question Is a Tumour Biology Question
Here is what most of the coverage missed. Intismeran sequences a patient’s resected tumour, identifies up to 34 patient-specific neoantigens, and encodes them in a bespoke mRNA construct. That approach needs raw material, mutations.
Melanoma, driven by UV mutagenesis, carries among the highest tumour mutational burdens in solid oncology. It is close to a best-case substrate for neoantigen selection, which is exactly why Leerink’s Daina Graybosch cautioned that melanoma may be uniquely suited to this approach.
So the read-across is not uniform. Non-small cell lung cancer, also high-TMB, should translate reasonably; bladder sits in a similar range. Renal cell carcinoma is the real test, RCC is notoriously low-TMB yet unusually immunotherapy-responsive, breaking the tidy link between mutation count and immune benefit. If intismeran works in kidney cancer, the platform is broader than melanoma biology. If it doesn’t, the field learns where individualized neoantigen therapy actually belongs. Nine Phase 2 and Phase 3 oncology studies are running across the collaboration, with mid-stage kidney and bladder data expected later this year or in 2027.
The Constraint Is Logistics
Each dose is manufactured for one patient. Turnaround now runs roughly six weeks from tissue to administration, down from the 50–60 days quoted in 2019, and Moderna’s Marlborough, Massachusetts facility began shipping patient batches in September 2025. Neither cost per dose nor annual capacity has been disclosed, a conspicuous silence given the company publishes capacity figures for its conventional vaccine plants.
Six weeks means the vaccine cannot be the first thing given after surgery; checkpoint blockade starts and the personalized product catches up. Tissue quality, sequencing turnaround, and cold chain become clinical variables rather than manufacturing footnotes. Adjuvant melanoma is a manageable volume. Lung cancer is not.
One footnote worth its own story: the surge returned Moderna cofounder Robert Langer, MIT engineer, “Edison of Medicine,” holder of a roughly 3% stake he has never sold, to billionaire status for the second time in his career.
Key Takeaway
The 177% was a single day’s opinion, and the 20% give-back the next session was another. What is durable is that individualized neoantigen therapy has cleared Phase 3 for the first time, and cancer vaccines are no longer a field defined by its failures. What remains unknown, the magnitude of benefit, the durability, the survival signal, and whether the biology travels beyond high-mutation tumours, will be settled at a podium, not on a tape.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada